$ 52.1
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of MTSR is 54 and suggests 4% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation sug
